Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

InMode Affirms Safety of Management, Employees and Production Sites

InMode Logo

News provided by

InMode LTD

09 Oct, 2023, 23:44 IDT

Share this article

Share toX

Share this article

Share toX

YOKNEAM, Israel, Oct. 9, 2023 /PRNewswire/ --  InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, addressed today the status of the Company's activity in Israel. 

Moshe Mizrahy, InMode's Chairman and Chief Executive Officer said: "InMode is committed to supporting all customers, distributors, employees, and salespeople worldwide. We prioritize the safety and well-being of our employees and will continue to do so as we execute our strategy."

"We don't anticipate any interruption to production. Our inventory levels globally and in Israel are sufficient and include components and subassemblies for the next three quarters. As a result, all platforms and consumables will be delivered on time and will meet the highest standards. In addition, InMode takes all required measures to ensure continuous customer support and exceptional service."

"Our Israeli employees are resilient and experienced in working during challenging times. We are all as committed as we have ever been to InMode's success, and this continues to be our focus. The contribution of revenues generated from Israel is less than 1%."

About InMode

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.

Forward-Looking Statements

The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the future performance described above under the heading titled "2023 Financial Outlook." Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, including with respect to the impact of the COVID-19 global outbreak. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 14, 2023, as well as risk factors relating to the COVID-19 global outbreak and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

Investor Relations Contact:

Miri Segal

MS-IR LLC

Phone: (917) 607-8654

Email: [email protected]

Logo: https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg

SOURCE InMode LTD

Modal title

Also from this source

InMode to Participate in the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference

InMode to Participate in the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer...

More Releases From This Source

Explore

Medical Pharmaceuticals

Medical Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

Medical Equipment

Medical Equipment

Accounting News & Issues

Accounting News & Issues

News Releases in Similar Topics

Contact PR Newswire

  • +972-77-2005042
    from 8 AM - 11 PM IL

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Csezh
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italie
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+972-77-2005042
from 8 AM - 11 PM IL
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.